Skip to search formSkip to main content

ponezumab

A humanized monoclonal antibody (IgG2deltaA) raised against amyloid beta peptides with Alzheimer disease treatment application. Ponezumab recognizes… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Objective Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of β-amyloid fragments leading to… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2017
2017
INTRODUCTION The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2017
2017
INTRODUCTION Multiple intravenous doses of ponezumab, an anti-amyloid antibody, were evaluated in subjects with mild-to-moderate… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Prominent cerebral amyloid angiopathy is often observed in the brains of elderly individuals and is almost universally found in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2014
Review
2014
  • Yu-Hui Liu, Ye-Ran Wang, +6 authors Yan-Jiang Wang
  • Molecular Neurobiology
  • 2014
Amyloid-beta (Aβ) is suggested to play a causal role in the pathogenesis of Alzheimer’s disease (AD). Immunotherapies are among… Expand
  • figure 1
Is this relevant?
2013
2013
OBJECTIVES Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). METHODS… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2013
2013
OBJECTIVE Ponezumab (PF-04360365) is a humanized anti-amyloid beta (Aβ) monoclonal antibody designed for treatment of Alzheimer… Expand
Is this relevant?
2012
2012
Ponezumab (PF-04360365) is a novel humanized IgG2Δa monoclonal antibody that binds to amyloid-β (Aβ). It is designed to have… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
2012
2012
Cerebral vasogenic edema and microhemorrhages are potential safety concerns for compounds intended to treat subjects with… Expand
Is this relevant?
2012
2012
Alzheimer's disease, the most common cause of dementia in the elderly and characterized by the deposition and accumulation of… Expand
Is this relevant?